RU 23. CMTM5 downregulates HER2 to inhibit prostate cancer

Objective: To observe the relation of HER2 and CMTM5 on prostate cancer.

Methods: For this purpose, we detected HER2 and CMTM5 on prostate cancer tissue chip. And we also compares the protein level of HER2 and CMTM5 with or without CMTM5 plasmid transfection on PC3 cell line to insure the relationship of them.

Results: We demonstrated that the HER2 has been up regulated in prostate cancer epithelium while CMTM5 down regulated. Overexpression of CMTM5 in PC3 could lower the HER2 protein level.

Conclusions: Taken together, our results seem to suggest that in prostate cancer HER2 has a different partner in the signaling transduction other than EGFR as in a traditional pathway. CMTM5 may has an chance to be chosen as the next potential treatment bio-target of prostate cancer.